Abstract
BackgroundStatin-fibrate combination therapy has been used to treat patients with acute coronary syndrome (ACS) complicated by elevated triglycerides (TG) and decreased high density lipoprotein cholesterol (HDL-C). The purpose of this study was to evaluate the influence of the combination therapy on lipids profile and apolipoprotein A5 (apoA5) level in patients with ACS.MethodsOne hundred and four patients with ACS were recruited and randomly assigned into two groups: one was statin group (n = 52), given atorvastatin (20 mg QN) or other statins with equivalent dosages; the other was combination group (n = 52), given the same dose of statin plus bezafibrate (200 mg BID). Follow-up visits were scheduled at the end of 6 and 12 weeks post treatment. Serum apoA5 levels were determined using a commercial available ELISA kit.Results(1) Compared with that of statin monotherapy, statin-bezafibrate combination treatment not only resulted in a significant reduction of TG, TC and LDL-C levels, (all p < 0.05), but also led to increases in HDL-C and apoA5 levels (p < 0.05).(2) The percentage changes of TC, TG, LDL-C and apoA5 levels in both groups were even bigger at 12 weeks after treatment than that at 6 weeks (all p < 0.05). Similarly, the rates of achieving lipid-control target were higher in statin-bezafibrate combination treatment group than those in statin monotherapy group (all p < 0.05).(3) Spearman rank correlation analysis showed that the pre-treatment apoA5 level was positively correlated with TG (r = 0.359, p = 0.009). However, a negative correlation was observed between apoA5 and TG (r = -0.329, p = 0.017) after 12 weeks treatment.ConclusionsStatin and fibrate combination therapy is more effective than statin alone in achieving a comprehensive lipid control for ACS patients. Serum apoA5 elevation after statin and fibrate combination treatment could be due to the synergistic effect of both drugs on hypertriglyceridemia control.
Highlights
Despite using intensive statin therapy, about 65% of coronary events can not be prevented in patients with coronary heart diseases
Serum apolipoprotein A5 (apoA5) elevation after statin and fibrate combination treatment could be due to the synergistic effect of both drugs on hypertriglyceridemia control
There were no significant differences between two groups in acute coronary syndrome (ACS) type (AMI/unstable angina (UA)), gender, age, body mass index, blood glucose, blood pressure, alanine aminotransferase, creatinine, and creatine kinase
Summary
Despite using intensive statin therapy, about 65% of coronary events can not be prevented in patients with coronary heart diseases. It was believed that the residual cardiovascular risk was partly associated with atherogenic dyslipidemia, including elevated triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL-C) [1]. The atherogenic dyslipidemia is likely to be controlled by statins and fibrates are involved in apoA5 gene expression [6,7,8,9,10]. The present study was to observe the effects of statin and fibrate combination treatment on serum lipids and apoA5 levels in patients with ACS. Statin-fibrate combination therapy has been used to treat patients with acute coronary syndrome (ACS) complicated by elevated triglycerides (TG) and decreased high density lipoprotein cholesterol (HDL-C). The purpose of this study was to evaluate the influence of the combination therapy on lipids profile and apolipoprotein A5 (apoA5) level in patients with ACS
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.